Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,274,240
  • Shares Outstanding, K 74,273
  • Annual Sales, $ 5,450 K
  • Annual Income, $ -325,100 K
  • EBIT $ -326 M
  • EBITDA $ -325 M
  • 60-Month Beta 0.79
  • Price/Sales 410.84
  • Price/Cash Flow N/A
  • Price/Book 4.01

Options Overview Details

View History
  • Implied Volatility 125.88% ( +13.79%)
  • Historical Volatility 28.73%
  • IV Percentile 99%
  • IV Rank 96.52%
  • IV High 128.76% on 11/27/23
  • IV Low 45.76% on 09/03/24
  • Put/Call Vol Ratio 1.40
  • Today's Volume 36
  • Volume Avg (30-Day) 207
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 8,833
  • Open Int (30-Day) 7,494

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.76
  • Number of Estimates 5
  • High Estimate -0.60
  • Low Estimate -0.95
  • Prior Year -1.27
  • Growth Rate Est. (year over year) +40.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.21 +9.68%
on 10/24/24
34.20 -9.53%
on 10/08/24
-1.70 (-5.21%)
since 10/04/24
3-Month
28.21 +9.68%
on 10/24/24
43.64 -29.10%
on 08/26/24
-2.49 (-7.45%)
since 08/02/24
52-Week
18.00 +71.89%
on 11/13/23
53.92 -42.62%
on 03/08/24
+6.63 (+27.27%)
since 11/03/23

Most Recent Stories

More News
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

SWTX : 30.94 (+1.05%)
SpringWorks Therapeutics: Q2 Earnings Snapshot

SpringWorks Therapeutics: Q2 Earnings Snapshot

SWTX : 30.94 (+1.05%)
SpringWorks Therapeutics: Q1 Earnings Snapshot

SpringWorks Therapeutics: Q1 Earnings Snapshot

SWTX : 30.94 (+1.05%)
5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

$SPX : 5,712.69 (-0.28%)
NVO : 109.72 (-1.98%)
BIIB : 173.52 (-0.16%)
KNSA : 21.48 (-4.43%)
SWTX : 30.94 (+1.05%)
RLAY : 5.85 (+0.17%)
ADPT : 5.26 (-0.94%)
GS : 511.47 (-1.52%)
SpringWorks Therapeutics: Q4 Earnings Snapshot

SpringWorks Therapeutics: Q4 Earnings Snapshot

SWTX : 30.94 (+1.05%)
SpringWorks Therapeutics: Q3 Earnings Snapshot

SpringWorks Therapeutics: Q3 Earnings Snapshot

SWTX : 30.94 (+1.05%)
SpringWorks Therapeutics: Q2 Earnings Snapshot

SpringWorks Therapeutics: Q2 Earnings Snapshot

SWTX : 30.94 (+1.05%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 3.62 (-4.74%)
DAWN : 14.81 (+1.09%)
SWTX : 30.94 (+1.05%)
VSTM : 3.90 (-0.51%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 3.62 (-4.74%)
SWTX : 30.94 (+1.05%)
DAWN : 14.81 (+1.09%)
VSTM : 3.90 (-0.51%)
KNTE : 2.65 (-0.38%)
SpringWorks Therapeutics: Q1 Earnings Snapshot

SpringWorks Therapeutics: Q1 Earnings Snapshot

SWTX : 30.94 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics...

See More

Key Turning Points

3rd Resistance Point 33.88
2nd Resistance Point 32.87
1st Resistance Point 31.90
Last Price 30.94
1st Support Level 29.92
2nd Support Level 28.91
3rd Support Level 27.94

See More

52-Week High 53.92
Fibonacci 61.8% 40.20
Fibonacci 50% 35.96
Fibonacci 38.2% 31.72
Last Price 30.94
52-Week Low 18.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar